T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.
Melanoma|Malignant Melanoma
COMBINATION_PRODUCT: T3011 + Cobimetinib
ORR, defined as the proportion of patients with a CR or PR on two consecutive occasions â‰¥ 4 weeks apart, as determined by the investigator according to RECIST version 1.1, up to 5 years after the first dose of the last patient, depending on the actual situation.|Characterize the safety and tolerability of T3011 in combination with Cobimetinib., Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs) (part 1 only), adverse event of special interest (AESIs), abnormal clinically significant vital signs, physical examination, and laboratory tests, with severity determined according to national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0., up to 5 years after the first dose of the last patient, depending on the actual situation.
Overall Survival (OS), defined as the time from initiation of study treatment to death from any cause, up to 5 years after the first dose of the last patient, depending on the actual situation.|Progression-free survival (PFS), defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST version 1.1, up to 5 years after the first dose of the last patient, depending on the actual situation.|Disease control rate (DCR), defined as the proportion of patients who have a best overall response of CR or PR or SD, as determined by the investigator according to RECIST version 1.1., up to 5 years after the first dose of the last patient, depending on the actual situation.|Duration of response (DOR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST version 1.1., up to 5 years after the first dose of the last patient, depending on the actual situation.|European Organization for Research and Treatment of Cancer Questionnaire Core 30 (EORTC QLQ-C30), Change from baseline in the European Organization for Research and Treatment of Cancer Questionnaire Core 30 (EORTC QLQ-C30) (version 3.0) at subsequent visits protocol required., up to 5 years after the first dose of the last patient, depending on the actual situation.
This is a phase 2a, open-label study of T3011 given via intratumoral (IT) injection in combination with Cobimetinib given via oral administration in patients with advanced melanoma. This study is planned to enroll approximately 62\~68 patients with BRAF V600E/V600K mutation-positive or RAS mutation-positive, which will be conducted in 2 parts (part 1 and part 2).